RefluxStop implantation
DeviceStandard surgical technique for implantation RefluxStop, as described in the Itructions for Use
NCT Number: NCT05870163
This post-market registry aims to assess safety and performance of RefluxStop™ in the treatment of Gastroesophageal Reflux Disease (GERD) in standard of care procedures.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Klinikum Friedrichshafen GmbH, Friedrichshafen, Germany
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Standard surgical technique for implantation RefluxStop, as described in the Itructions for Use
Standard of care Nissen fundoplication surgery
Time frame: 6 months
Incidence of Serious Adverse Device Effects (SADEs), Serious Adverse Events (SAEs) and Device Deficiencies (DDs)
Time frame: 6 months
Assessment of GERD symptoms, measured by GERD Health-Related Quality of Life (HRQL) score (questions 1-10).
(An answer of zero means no symptoms)
Time frame: 3 and 6 months and annually up to 5 years
Incidence of Serious Adverse Device Effects (SADEs), Serious Adverse Events (SAEs) and Device Deficiencies (DDs) at 3 months and annually up to 5 years.
Plus Incidence of Adverse Device Effects (ADEs) and procedure related or unknown Adverse Events (AEs) at 3 and 6 months and annually up to 5 years
Time frame: 3 months and annually up to 5 years
Assessment of GERD symptoms, assessed by GERD-HRQL score (questions 1-10)
Time frame: 6 months
Location and function of the device evaluated by a simplified contrast swallow x-ray with overview pictures of device
Time frame: 6 months
Location of baseline hernia or any new hernia by a simplified contrast swallow x-ray picture
Time frame: 6 months
Reduction or normalisation from baseline of the total acid (pH<4) exposure time during 24-hour pH monitoring
Time frame: 3 and 6 months and annually up to 5 years
EQ-5D (Euro Quality of life-5 Dimension) questionnaire: measure of quality of life with one question for each of the five dimensions that are mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. For each dimension, the patients assess if they have no problem, slight, moderate, severe or extreme problems.
Time frame: 3 and 6 months and annually up to 5 years
WPAI (work related productivity gains): 5 questions to assess how health problems effect the patient work Score 0 to 10. Zero meaning health problems have no effect on work
Time frame: 3 and 6 months and annually up to 5 years
Evaluation of number of visit to the General Practitioner
Time frame: 3 and 6 months and annually up to 5 years
Counting of the number of patients using PPI (Proton Pump Inhibitors)
Time frame: 3 and 6 months and annually up to 5 years
Counting of the number of re-admission to hospital due to complications
Time frame: 3 and 6 months and annually up to 5 years
Evaluation of the costs related to the study procedure and the length of hospital stay
Contact information is provided by the study sponsor or research team.
Implantica CE Reflux Ltd.
Industry
A Post-market Registry Study to Assess Safety and Performance of RefluxStop™ in the Treatment of Gastroesophageal Reflux Disease (GERD) in General Hospital Practice
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04506593
Chronic Intestinal Pseudo-obstruction, Colonic Diseases
Indianapolis, Indiana, United States
View Trial DetailsNCT00260585
Deglutition Disorders, Digestive System Diseases
Pittsburgh, Pennsylvania, United States
View Trial DetailsNCT06984484
Deglutition Disorders, Digestive System Diseases
Genova, Italy
View Trial DetailsNCT06564246
Deglutition Disorders, Digestive System Diseases
Giza, Egypt
View Trial Details